ABSTRACT:

Introduction: Gastrointestinal Stromal Tumors (GISTs) are the leading type of mesenchymal tumor in the gastrointestinal (GI) tract, constituting 80% of these tumors and 0.1% to 3% of all gastrointestinal malignancies. They arise from spindle-shaped mesenchymal cells known as interstitial cells of Cajal. Its onset can be at any age, with the peak occurring in the sixth decade.
Case Presentation: We report the case of a 34-year-old woman with a complaint about a lump in her lower abdomen that has been progressively enlarging over the past year without any significant symptoms following the lump. Findings in the ultrasound suggest an ovarian mass. Laparotomy was carried out, and while no ovarian mass was found, instead a mass was identified in the mesentery of the small bowel. As a result, a complete excision of the tumor was performed, with histopathologic and immunohistochemical results confirming a GIST diagnosis.
Conclusion: Representing a tiny percentage of gastrointestinal tumors, GISTs are rare. GISTs may be asymptomatic or present without any typical symptoms. Sole reliance on clinical and radiological investigations can cause them to be easily overlooked. Awareness of GIST is critical and care must be taken in diagnosis since other tumor can mimic GISTs in endoscopic, imaging, and histological findings.

KEYWORDS:

Gastrointestinal Stromal Tumors, GIST, Extragastrointestinal Stromal Tumors, EGIST, CD117

REFERENCES :

1) El-Menyar A, Mekkodathil A, Al-Thani H. Diagnosis and management of gastrointestinal stromal tumors: An up-to-date literature review. J Cancer Res Ther. 2017 Oct-Dec;13(6):889-900.
2) Fülöp E, Marcu S, Milutin D, et al. Gastrointestinal stromal tumors: review on morphology, diagnosis and management. Rom J Morphol Embryol 2009;50:319–26.
3) Rossi CR, Mocellin S, Mencarelli R, et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 2003;107:171–6.
4) Rubin, B.P. ‘Gastrointestinal Stromal Tumor (GIST) and Extragastrointestinal GIST ‘ in Goldblum, J.R, Folpe, A.L, Weiss, S.W. (7th ed). Enzinger and Weiss’s Soft Tissue Tumors. Elsevier. 2021. pp 614
5) Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu R. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies, Cancer Epidemiology. Available at: https://www.sciencedirect.com/science/article/pii/S1877782115002519?via%3Dihub
6) Dualim DM, Loo GH, Rajan R, Nik Mahmood NR. Jejunal GIST: hunting down an unusual cause of gastrointestinal bleed using double balloon enteroscopy. A case report. Int J Surg Case Rep. 2019;60:303–306.
7) Von Mehren M, Kane JM, Armstrong SA, et al. National Comprehensive Cancer Network; 2023. NCCN Clinical Practice Guidelines in Oncology: Gastrointestinal Stromal Tumors, Version 1.2023.
8) Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003;54:3–24.
9) Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33(5):459–65.
10) Fagkrezos D, Touloumis Z, Giannila M, et al.. Extra-gastrointestinal stromal tumor of the omentum: a rare case report and review of the literature. Rare Tumors. 2012;4:e44.
11) Extragastrointestinal stromal tumour (EGIST) presented as a mesenteric and retroperitoneal mass. Costa Almeida C, Caroço TV, Albano M, Carvalho L. BMJ Case Rep. 2019 
12) Bucher P, Villiger P, Egger JF, Buhler LH, Morel P. Management of gastrointestinal stromal tumors: From diagnosis to treatment Swiss Med Wkly. 2004
13) Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Reith JD, Goldblum JR, Lyles RH, Weiss SW. Mod Pathol. 2000;13:577–585
14) Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016 Jan;19(1):3-14.
15) Clinicopathological and treatment analysis of 13 extragastrointestinal stromal tumors of mesentery and retroperitoneum. Iqbal N, Sharma A, Iqbal N. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289982/pdf/AOG-28-105.pdf. Ann Gastroenterol. 2015;28:105–108.
16) Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, Cameron S, Hohenberger P, Jost PJ, Al-Batran SE, Lindner LH, Bauer S, Wardelmann E, Nilsson B, Kallio R, Jaakkola P, Junnila J, Alvegård T, Reichardt P. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol. 2020;6:1241–1246.
17) Sugiyama Y, Sasaki M, Kouyama M, Tazaki T, Takahashi S, Nakamitsu A. Current treatment strategies and future perspectives for gastrointestinal stromal tumors. World J Gastrointest Pathophysiol. 2022 Jan 22;13(1):15-33.
18) Reichardt P., Blay J.-Y., Boukovinas I., Brodowicz T., Broto J.M., Casali P.G., Decatris M., Eriksson M., Gelderblom H., Kosmidis P., et al. Adjuvant therapy in primary GIST: State-of-the-art. Ann. Oncol. 2012;23:2776–2781.
19) Joseph C.P., Abaricia S.N., Angelis M.A., Polson K., Jones R.L., Kang Y.K., Riedel R.F., Schöffski P., Serrano C., Trent J., et al. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist. 2021;26:e622
20) Heinrich M.C., Jones R.L., von Mehren M., Schöffski P., Serrano C., Kang Y.K., Cassier P.A., Mir O., Eskens F., Tap W.D., et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): A multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21:935.